CARM
Carisma Therapeutics, Inc.
Price Chart
Latest Quote
$0.02
+0.02 (+261.02%)
Current Price
| Previous Close | $0.01 |
| Open | $0.03 |
| Day High | $0.03 |
| Day Low | $0.03 |
| Volume | 10,296 |
Stock Information
| Shares Outstanding | 41.85M |
| Total Debt | $762K |
| Cash Equivalents | $2.78M |
| Revenue | $52.63M |
| Net Income | $8.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $891K |
| P/E Ratio | 0.11 |
| EPS (TTM) | $0.19 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-1.12M |
| Sales | $52.63M |
| Income | $8.04M |
| Book/sh | $-0.02 |
| Cash/sh | $0.07 |
| Employees | 46 |
Financial Ratios
| Quick Ratio | 0.65 |
| Current Ratio | 0.86 |
Returns & Margins
| ROA | 33.03% |
| Gross Margin | 48.03% |
| Operating Margin | 96.83% |
| Profit Margin | 15.28% |
Ownership
| Insider Ownership | 26.56% |
| Institutional Ownership | 10.79% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.02 |
| P/S | 0.02 |
| P/B | -1.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.01 |
| SMA200 | $0.07 |
| RSI | 63.61 |
| ATR | 0.0092 |
| Shares Float | 30.14M |
| Short Float | 3.57% |
| Short Ratio | 0.06 |
| Volatility | 0.80 |
| Rel Volume | 0.40 |
Performance History
| Week | +1231.25% |
| Month | +21200.00% |
| Quarter | -43.35% |
| 6 Months | -61.72% |
| YTD | -51.59% |
| Year | -95.28% |
| 3 Years | -99.65% |
| 10 Years | -99.42% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $0.02 | 22,184 |
| 2026-06-15 | $0.01 | 3,413 |
| 2026-06-12 | $0.01 | 6,541 |
| 2026-06-11 | $0.01 | 476,788 |
| 2026-06-10 | $0.02 | 123,382 |
| 2026-06-09 | $0.00 | 81,721 |
| 2026-06-08 | $0.02 | 128,748 |
| 2026-06-05 | $0.00 | 9,315 |
| 2026-06-04 | $0.00 | 11,554 |
| 2026-06-03 | $0.00 | 2,199 |
| 2026-06-02 | $0.00 | 54,361 |
| 2026-06-01 | $0.00 | 52,507 |
| 2026-05-29 | $0.00 | 4,155 |
| 2026-05-28 | $0.00 | 62,286 |
| 2026-05-27 | $0.00 | 10,519 |
| 2026-05-26 | $0.00 | 9,696 |
| 2026-05-22 | $0.00 | 1,846 |
| 2026-05-21 | $0.00 | 18,699 |
| 2026-05-20 | $0.00 | 26,831 |
| 2026-05-19 | $0.00 | 1,452 |
| 2026-05-18 | $0.00 | 15,208 |
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $19,632,000 | $14,919,000 | $9,834,000 | $0 |
| Operating Revenue | $19,632,000 | $14,919,000 | $9,834,000 | $0 |
| Expenses | ||||
| Total Expenses | $81,811,000 | $103,650,000 | $65,996,000 | $40,794,000 |
| Net Non Operating Interest Income Expense | $1,702,000 | $1,936,000 | $-3,145,000 | $10,000 |
| Operating Expense | $81,811,000 | $103,650,000 | $65,996,000 | $40,794,000 |
| General And Administrative Expense | $22,138,000 | $29,525,000 | $9,378,000 | $6,407,000 |
| Other Income Expense | - | $-84,000 | $-1,919,000 | - |
| Interest Expense | - | - | $3,145,000 | - |
| Interest Expense Non Operating | - | - | $3,145,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Net Interest Income | $1,702,000 | $1,936,000 | $-3,145,000 | $10,000 |
| Interest Income | $1,702,000 | $1,936,000 | - | $10,000 |
| Normalized Income | $-60,477,000 | $-86,795,000 | $-59,307,000 | $-40,784,000 |
| Net Income From Continuing And Discontinued Operation | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Total Operating Income As Reported | $-62,179,000 | $-88,731,000 | $-56,162,000 | $-40,794,000 |
| Net Income Common Stockholders | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Net Income | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Net Income Including Noncontrolling Interests | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Net Income Continuous Operations | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Pretax Income | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Interest Income Non Operating | $1,702,000 | $1,936,000 | - | $10,000 |
| Operating Income | $-62,179,000 | $-88,731,000 | $-56,162,000 | $-40,794,000 |
| Per Share | ||||
| Diluted EPS | $-1.46 | $-2.59 | $-1.52 | $-1.01 |
| Basic EPS | $-1.46 | $-2.59 | $-1.52 | $-1.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-58,825,000 | $-85,810,000 | $-54,269,000 | $-40,112,000 |
| Reconciled Depreciation | $3,354,000 | $2,837,000 | $1,893,000 | $682,000 |
| EBITDA (Bullshit earnings) | $-58,825,000 | $-85,894,000 | $-56,188,000 | $-40,112,000 |
| EBIT | $-62,179,000 | $-88,731,000 | $-58,081,000 | $-40,794,000 |
| Diluted Average Shares | $41,456,210 | $33,524,197 | $40,254,666 | $40,254,666 |
| Basic Average Shares | $41,456,210 | $33,524,197 | $40,254,666 | $40,254,666 |
| Diluted NI Availto Com Stockholders | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Research And Development | $59,673,000 | $74,125,000 | $56,618,000 | $34,387,000 |
| Selling General And Administration | $22,138,000 | $29,525,000 | $9,378,000 | $6,407,000 |
| Other Gand A | $11,039,000 | $15,964,000 | $5,770,000 | $3,961,000 |
| Insurance And Claims | $1,351,000 | $2,890,000 | $211,000 | - |
| Salaries And Wages | $9,748,000 | $10,671,000 | $3,397,000 | $2,446,000 |
| Total Unusual Items | - | $-84,000 | $-1,919,000 | - |
| Total Unusual Items Excluding Goodwill | - | $-84,000 | $-1,919,000 | - |
| Gain On Sale Of Security | - | $-84,000 | $-1,919,000 | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-27,909,000 | $26,532,000 | $-157,065,000 | $11,629,000 |
| Total Assets | $30,458,000 | $89,554,000 | $72,153,000 | $35,449,000 |
| Total Non Current Assets | $6,633,000 | $9,083,000 | $17,561,000 | $5,663,000 |
| Non Current Deferred Assets | $208,000 | $146,000 | $4,111,000 | - |
| Current Assets | $23,825,000 | $80,471,000 | $54,592,000 | $29,786,000 |
| Other Current Assets | $5,916,000 | $2,866,000 | $2,596,000 | $1,235,000 |
| Cash Cash Equivalents And Short Term Investments | $17,909,000 | $77,605,000 | $51,996,000 | $28,551,000 |
| Cash And Cash Equivalents | $17,909,000 | $77,605,000 | $24,194,000 | $28,551,000 |
| Prepaid Assets | - | - | - | $1,235,000 |
| Debt | ||||
| Total Debt | $2,481,000 | $3,123,000 | $40,164,000 | $2,632,000 |
| Long Term Debt And Capital Lease Obligation | $744,000 | $1,188,000 | $35,565,000 | $1,734,000 |
| Current Debt And Capital Lease Obligation | $1,737,000 | $1,935,000 | $4,599,000 | $898,000 |
| Net Debt | - | - | $9,523,000 | - |
| Long Term Debt | - | - | $33,717,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $58,367,000 | $63,022,000 | $214,823,000 | $9,425,000 |
| Total Non Current Liabilities Net Minority Interest | $42,312,000 | $47,114,000 | $195,153,000 | $1,734,000 |
| Other Non Current Liabilities | $318,000 | $926,000 | $1,041,000 | - |
| Non Current Deferred Liabilities | $41,250,000 | $45,000,000 | $45,000,000 | - |
| Current Liabilities | $16,055,000 | $15,908,000 | $19,670,000 | $7,691,000 |
| Other Current Liabilities | $1,060,000 | $965,000 | $523,000 | - |
| Current Deferred Liabilities | $3,729,000 | $1,413,000 | $2,459,000 | - |
| Payables And Accrued Expenses | $4,650,000 | $8,495,000 | $9,280,000 | $6,793,000 |
| Payables | $2,081,000 | $3,933,000 | $1,728,000 | $2,322,000 |
| Accounts Payable | $2,081,000 | $3,933,000 | $1,728,000 | $2,322,000 |
| Derivative Product Liabilities | - | $0 | $5,739,000 | - |
| Interest Payable | - | $0 | $1,126,000 | - |
| Equity | ||||
| Common Stock Equity | $-27,909,000 | $26,532,000 | $-157,065,000 | $-96,179,000 |
| Total Equity Gross Minority Interest | $-27,909,000 | $26,532,000 | $-142,670,000 | $26,024,000 |
| Stockholders Equity | $-27,909,000 | $26,532,000 | $-157,065,000 | $11,629,000 |
| Retained Earnings | $-305,579,000 | $-245,102,000 | $-158,223,000 | $-96,997,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $-41,000 | - |
| Preferred Securities Outside Stock Equity | - | $0 | $107,808,000 | - |
| Other Equity Adjustments | - | - | $-41,000 | - |
| Preferred Stock Equity | - | - | - | $107,808,000 |
| Other | ||||
| Ordinary Shares Number | $41,750,109 | $40,609,915 | $40,254,666 | $40,254,666 |
| Share Issued | $41,750,109 | $40,609,915 | $40,254,666 | $40,254,666 |
| Tangible Book Value | $-27,909,000 | $26,532,000 | $-157,065,000 | $-96,179,000 |
| Invested Capital | $-27,909,000 | $26,532,000 | $-123,348,000 | $-96,179,000 |
| Working Capital | $7,770,000 | $64,563,000 | $34,922,000 | $22,095,000 |
| Capital Lease Obligations | $2,481,000 | $3,123,000 | $6,447,000 | $2,632,000 |
| Total Capitalization | $-27,909,000 | $26,532,000 | $-123,348,000 | $11,629,000 |
| Additional Paid In Capital | $277,629,000 | $271,594,000 | $1,197,000 | $818,000 |
| Capital Stock | $41,000 | $40,000 | $2,000 | $107,808,000 |
| Common Stock | $41,000 | $40,000 | $2,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $107,808,000 |
| Non Current Deferred Revenue | $41,250,000 | $45,000,000 | $45,000,000 | - |
| Long Term Capital Lease Obligation | $744,000 | $1,188,000 | $1,848,000 | $1,734,000 |
| Current Deferred Revenue | $3,729,000 | $1,413,000 | $2,459,000 | - |
| Current Capital Lease Obligation | $1,737,000 | $1,935,000 | $4,599,000 | $898,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,879,000 | $3,100,000 | $2,809,000 | - |
| Current Accrued Expenses | $2,569,000 | $4,562,000 | $7,552,000 | $4,471,000 |
| Net PPE | $6,425,000 | $8,937,000 | $13,450,000 | $5,663,000 |
| Accumulated Depreciation | $-7,887,000 | $-6,151,000 | $-3,314,000 | $-1,421,000 |
| Gross PPE | $14,312,000 | $15,088,000 | $16,764,000 | $7,084,000 |
| Leases | $340,000 | $340,000 | $340,000 | $317,000 |
| Construction In Progress | $0 | $13,000 | $13,000 | $13,000 |
| Other Properties | $13,197,000 | $13,565,000 | $15,082,000 | $6,273,000 |
| Machinery Furniture Equipment | $775,000 | $1,170,000 | $1,329,000 | $481,000 |
| Properties | $0 | $0 | $0 | $0 |
| Minority Interest | - | $0 | $14,395,000 | $14,395,000 |
| Other Short Term Investments | - | $0 | $27,802,000 | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-60,040,000 | $-82,309,000 | $-9,776,000 | $-39,199,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-59,917,000 | $-81,177,000 | $-5,116,000 | $-37,328,000 |
| Cash Flow From Continuing Operating Activities | $-59,917,000 | $-81,177,000 | $-5,116,000 | $-37,328,000 |
| Operating Gains Losses | $-33,000 | $-156,000 | $1,919,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-123,000 | $-1,132,000 | $-4,660,000 | $-1,871,000 |
| Investing Cash Flow | $-123,000 | $72,408,000 | $-32,560,000 | $-1,871,000 |
| Cash Flow From Continuing Investing Activities | $-123,000 | $72,408,000 | $-32,560,000 | $-1,871,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,392,000 | $31,237,000 | $0 | $16,328,000 |
| Financing Cash Flow | $344,000 | $62,180,000 | $33,319,000 | $15,962,000 |
| Cash Flow From Continuing Financing Activities | $344,000 | $62,180,000 | $33,319,000 | $15,962,000 |
| Net Other Financing Charges | $-623,000 | $32,057,000 | $-922,000 | $-366,000 |
| Net Common Stock Issuance | $2,392,000 | $31,237,000 | $0 | - |
| Common Stock Issuance | $2,392,000 | $31,237,000 | $0 | - |
| Net Preferred Stock Issuance | - | - | - | $16,328,000 |
| Preferred Stock Issuance | - | - | - | $16,328,000 |
| Other | ||||
| Repayment Of Debt | $-1,429,000 | $-1,301,000 | $-865,000 | - |
| Interest Paid Supplemental Data | $192,000 | $352,000 | $98,000 | - |
| End Cash Position | $17,909,000 | $77,605,000 | $24,194,000 | $28,551,000 |
| Beginning Cash Position | $77,605,000 | $24,194,000 | $28,551,000 | $51,788,000 |
| Changes In Cash | $-59,696,000 | $53,411,000 | $-4,357,000 | $-23,237,000 |
| Proceeds From Stock Option Exercised | $4,000 | $187,000 | $106,000 | $0 |
| Net Issuance Payments Of Debt | $-1,429,000 | $-1,301,000 | $34,135,000 | - |
| Net Long Term Debt Issuance | $-1,429,000 | $-1,301,000 | $34,135,000 | - |
| Long Term Debt Payments | $-1,429,000 | $-1,301,000 | $-865,000 | - |
| Net Investment Purchase And Sale | $0 | $73,540,000 | $-27,900,000 | - |
| Sale Of Investment | $0 | $108,000,000 | $63,000,000 | - |
| Purchase Of Investment | $0 | $-34,460,000 | $-90,900,000 | - |
| Net PPE Purchase And Sale | $-123,000 | $-1,132,000 | $-4,660,000 | $-1,871,000 |
| Purchase Of PPE | $-123,000 | $-1,132,000 | $-4,660,000 | $-1,871,000 |
| Change In Working Capital | $-11,952,000 | $-5,436,000 | $45,196,000 | $1,461,000 |
| Change In Other Working Capital | $-1,434,000 | $-1,046,000 | $47,459,000 | - |
| Change In Other Current Liabilities | $-5,333,000 | $-4,728,000 | $-4,659,000 | $-813,000 |
| Change In Payables And Accrued Expense | $-2,065,000 | $-708,000 | $3,757,000 | $2,021,000 |
| Change In Accrued Expense | $-213,000 | $-2,899,000 | $4,230,000 | $2,995,000 |
| Change In Payable | $-1,852,000 | $2,191,000 | $-473,000 | $-974,000 |
| Change In Account Payable | $-1,852,000 | $2,191,000 | $-473,000 | $-974,000 |
| Change In Prepaid Assets | $-3,120,000 | $1,046,000 | $-1,361,000 | $253,000 |
| Other Non Cash Items | $5,180,000 | $6,850,000 | $6,827,000 | $834,000 |
| Stock Based Compensation | $3,649,000 | $2,316,000 | $275,000 | $479,000 |
| Asset Impairment Charge | $362,000 | $0 | - | - |
| Amortization Of Securities | $0 | $-709,000 | $0 | - |
| Depreciation Amortization Depletion | $3,354,000 | $2,837,000 | $1,893,000 | $682,000 |
| Depreciation And Amortization | $3,354,000 | $2,837,000 | $1,893,000 | $682,000 |
| Gain Loss On Sale Of PPE | $-33,000 | $159,000 | $0 | - |
| Net Income From Continuing Operations | $-60,477,000 | $-86,879,000 | $-61,226,000 | $-40,784,000 |
| Issuance Of Debt | - | $0 | $35,000,000 | - |
| Long Term Debt Issuance | - | $0 | $35,000,000 | - |
| Gain Loss On Investment Securities | - | $-315,000 | $1,919,000 | - |
Fetched: 2026-02-02